TRED-HF Recovery Relapse Prediction Model

Clinical calculation support · Verify results before clinical use

Clinical context review

Enter available baseline characteristics to create a structured review. This tool does not calculate a validated relapse score.

NO VALIDATED SCORE
Important clinical limitation. No externally validated TRED-HF bedside equation supports the coefficients in the original draft. To avoid presenting a fabricated probability, this version records the variables and provides evidence-based context only.
The original TRED-HF population had recovered LVEF ≥50% at enrolment.
Use the laboratory-reported value and unit. NT-proBNP and BNP are not interchangeable.
Count ACEi/ARB/ARNi, beta-blocker, MRA and SGLT2 inhibitor classes; maximum 4.

About TRED-HF and relapse

TRED-HF was a pilot randomized trial of phased withdrawal of pharmacological treatment in selected patients with previously dilated cardiomyopathy whose left ventricular function had recovered. In the original trial, approximately 40% of participants assigned to withdraw treatment relapsed within six months.

In long-term follow-up, 33 of 51 participants (65%) experienced relapse over a median follow-up of six years. The estimated five-year relapse rate from enrolment was 61% (95% CI 45–73%). These are cohort-level observations, not a personalized estimate for an individual patient.

Relapse definition used in follow-up

The long-term report defined relapse as a reduction in LVEF of at least 10 percentage points to below 50%, doubling of NT-proBNP to above 400 ng/L, or clinical features of heart failure. Criteria and protocol details differed across trial and post-trial follow-up; refer to the original publication for exact definitions at each phase.

Clinical use

  • Do not interpret recovery of LVEF as proof of permanent cure.
  • Do not use this page to estimate an individual patient's probability of relapse or to support medication withdrawal.
  • Continue guideline-directed therapy unless a treating specialist identifies a compelling individualized reason to modify it.
  • Consider ongoing clinical review, cardiac imaging and natriuretic peptide monitoring according to the patient's clinical context.

Evidence and limitations

Halliday BP, Wassall R, Lota AS, et al.Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. The Lancet. 2019;393(10166):61–73.doi:10.1016/S0140-6736(18)32484-X · Full text (PMC)
Cheng L, Hammersley D, Ragavan A, et al.Long-term follow-up of the TRED-HF trial: Implications for therapy in patients with dilated cardiomyopathy and heart failure remission. European Journal of Heart Failure. 2025;27(1):113–123.doi:10.1002/ejhf.3475 · PMID: 39349993
Model status: not validated. The original draft's logistic coefficients and low/moderate/high thresholds were illustrative choices, not published TRED-HF coefficients. They have intentionally been removed.
Clinical disclaimer: This educational tool is not a validated prognostic model, is not a substitute for professional judgement, and must not be used to direct treatment or withdrawal of heart failure medication. Input range checks are technical validation only; they do not establish clinical appropriateness.